title: Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer.
abstract: This chapter reviews some of the sentinel Gynecologic Oncology Group (GOG) ovarian trials, describes their rationale, provides summary tables for reference, and is organized into early ovarian cancer (GOG 1, 7601, 7602, 95, 157, 175, 212), advanced ovarian cancer optimal (2, 25, 52, 104, 114, 158, 172, 182, 178, 212, 252), and suboptimal disease (3, 22, 47, 97, 111, 162, 182, 218, 252, 262).
authors.affiliation: Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, Spectrum Health Medical Group and Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA. Leigh.Seamon@spectrumhealth.org
authors.forename: Leigh G
authors.initials: LG
authors.lastname: Seamon
authors.forename: Debra L
authors.initials: DL
authors.lastname: Richardson
authors.forename: Larry J
authors.initials: LJ
authors.lastname: Copeland
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007813:Laparotomy; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000473:pathology / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000627:therapeutic use; D011099:Polyglutamic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D024162:Second-Look Surgery
chemical_list: D011099:Polyglutamic Acid; D016190:Carboplatin; D017239:Paclitaxel; C509139:paclitaxel poliglumex